PGEN
Precigen, Inc.
There isn't enough reported data to score PGEN yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
PGEN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
PGEN's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
PGEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 7.2x | $4.66 | — |
| Cheap | 7.9x | $0.55 | -88% |
| Fair | 9.5x | $0.66 | -86% |
| Expensive | 14x | $0.98 | -79% |
| Current | 67x | $4.66 | — |
Historical ranges are pointers, not guarantees.
PGEN's PE is 67x, but its earnings don't support one, so it isn't a reliable read right now.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH has the edge over PGEN in the historical PE scenario, which offers more potential upside but is not a forecast.
PGEN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
PGEN has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
PGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.65 | +829% |
| Q3 2026 | $0.07 | +$1.45 |
| Q2 2026 | -$1.07 | -$0.66 |
| Q1 2026 | -$1.21 | -$0.66 |
| Q4 2025 | -$1.37 | -$0.90 |
| Q3 2025 | -$1.38 | -$0.83 |
| Q2 2025 | -$0.41 | +$0.13 |
| Q1 2025 | -$0.55 | -$0.16 |
| Q4 2024 | -$0.47 | -$0.08 |
PGEN has returned to profit: it earned $0.07 per share over the past year, after losing money the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over PGEN on earnings, with more consistent year-over-year improvement.
PGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $1.8M | -39% |
| Q1 2023 | $1.9M | -94% |
| Q4 2022 | $1.8M | -93% |
| Q3 2022 | $16.7M | -22% |
| Q2 2022 | $2.9M | -91% |
| Q1 2022 | $32M | +31% |
| Q4 2021 | $24.2M | +25% |
| Q3 2021 | $21.6M | -8.6% |
PGEN has the stronger quarterly revenue trend. Revenue is up 3,906% for PGEN versus down 0.4% for UNH.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 52% | N/A |
| Q2 2026 | 41% | N/A |
| Q1 2026 | -26% | N/A |
| Q2 2023 | -1154% | -255 points |
| Q1 2023 | -1231% | -1171 points |
| Q4 2022 | -1257% | -1154 points |
| Q3 2022 | -46% | +93 points |
| Q2 2022 | -898% | -838 points |
PGEN has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
PGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.4M | +$40.9M |
| Q2 2026 | -$18.2M | +$1.7M |
| Q1 2026 | -$44.1M | -$27.1M |
| Q4 2025 | -$23.5M | -$14.2M |
| Q3 2025 | -$29.5M | -$5.8M |
| Q2 2025 | -$19.9M | +$5.5M |
| Q1 2025 | -$16.9M | +$1.5M |
| Q4 2024 | -$9.3M | +$7.5M |
PGEN has burned cash in almost every quarter: −$74M over the past year, against −$76M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over PGEN on cash generation, producing positive trailing cash flow while its opponent burns cash.
PGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +7.5M shares |
| 1 year | +37% | +114M shares |
| 3 years | +69% | +173M shares |
| 5 years | +112% | +222M shares |
| Available history | +173% | +267M shares |
PGEN has 421M diluted shares, up 37% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over PGEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
PGEN Net Leverage
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
PGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.6 | Neutral |
| Stochastic | 23.8 | Neutral |
PGEN's weekly RSI is 43 (neutral) and its Stochastic is 24 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
PGEN PE vs Healthcare Sector
| Metric | PGEN | Sector median | Relative |
|---|---|---|---|
| PE | 67x | 26x | 158% above |
| PE % | 100 | 29 | 71 pts above |
PGEN is trading at 67x earnings, a 158% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over PGEN on valuation relative to its sector.
PGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.59 | 29% below |
| 20 week MA | $6.48 | 28% below |
| 50 week MA | $5.10 | 8.6% below |
| 100 week MA | $3.68 | 27% above |
| 200 week MA | $2.48 | 88% above |
PGEN has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 88% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over PGEN on trend strength, trading above more of its moving averages.
PGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.74 | $10.0 | +75% |
| 2021 | $10.0 | $4.10 | -59% |
| 2022 | $4.10 | $1.40 | -66% |
| 2023 | $1.40 | $1.34 | -4.3% |
| 2024 | $1.34 | $0.73 | -46% |
| 2025 | $0.73 | $4.16 | +470% |
| 2026 YTD | $4.16 | $4.66 | +12% |
PGEN's yearly returns have swung widely, from +470% in 2025 to −66% in 2022. It's up 12% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over PGEN on returns for 2026, with the stronger performance.